Derma Sciences Inc. (NASDAQ:DSCI) shares saw strong trading volume on Tuesday . 81,222 shares were traded during mid-day trading, an increase of 48% from the previous session’s volume of 54,987 shares.The stock last traded at $4.71 and had previously closed at $4.70.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Derma Sciences from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Wednesday, August 3rd. TheStreet raised Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $7.35.

The company’s market capitalization is $137.00 million. The firm has a 50 day moving average of $4.76 and a 200 day moving average of $3.89.

Derma Sciences (NASDAQ:DSCI) last announced its earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.16. The company had revenue of $22.20 million for the quarter, compared to analysts’ expectations of $22.40 million. On average, analysts anticipate that Derma Sciences Inc. will post ($0.04) EPS for the current year.

A hedge fund recently raised its stake in Derma Sciences stock. Jennison Associates LLC increased its stake in shares of Derma Sciences Inc. (NASDAQ:DSCI) by 22.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,407,506 shares of the company’s stock after buying an additional 261,818 shares during the period. Jennison Associates LLC owned 5.45% of Derma Sciences worth $6,432,000 as of its most recent filing with the SEC.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.